Angiotensin Receptor Blockers in Aortic Stenosis

• Status: Recruiting
• Trial end date: 2025-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is intended to investigate the effect of angiotensin receptor blockers (ARBs) on mild-to-moderate aortic stenosis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
• Collaborator: Odense University Hospital
• Treatments: Angiotensin Receptor Antagonists

Criteria

Inclusion Criteria:

• Mild to moderate aortic stenosis (peak aortic jet velocity ≥2.5 and <4m/s)

• Normal left ventricular ejection fraction (i.e. ≥50%)

• Systolic blood pressure >110 mmHg

• Diastolic blood pressure >70 mmHg

Exclusion Criteria:

• More than mild aortic or mitral regurgitation, or mitral stenosis

• Current use or documented indication for renin-angiotensin system medication or Aliskiren

• Known allergy or intolerance to angiotensin II receptor blockers (ARBs)

• Alzheimer, dementia or known non-compliant patient

• Renal dysfunction (glomerular filtration rate <30ml/min/1.73m2)

• Chronic hyperkalemia

• Diagnosed hepatic failure, cirrhosis, hepatitis or history of hepatic impairment

• Newly diagnosed (<2 months) or poorly controlled diabetes

• Pre-existing obstructive coronary artery disease with CCS III-IV angina or recent myocardial infarction (<3 months)

• Pregnant or lactating women

• Patients unable to read, understand or sign research consent